hit counter
AVROBIO, Inc. (AVRO) Stock News Sentiment & Price - Sentifly
AVRO - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



AVROBIO, Inc. (AVRO)

USA
Biotechnology
NASDAQ
AVRO Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AVRO Latest news
Business Wire
Neutral
AVROBIO to Present at Two Upcoming Investor Conferences in November
2021-11-09 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: Barclays Gene Editing & Gene Therapy Summit Date: Monday, Nov. 15, 2021 Time: 2:30 p.m. ET Stifel 2021 Virtual Healthcare Conference Date: Wednesday, Nov. 17, 2021 Time: 10:00 a.m. ET A live w

Business Wire
Neutral
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
2021-11-08 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present safety data from its clinical trials in Fabry disease and Gaucher disease type 1 at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) on Nov. 21-23, 2021, in Sydney, Australia. Clinical and preclinical data from the company's pipeline of lysosomal disorder program

Business Wire
Neutral
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021-11-05 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 120,000 shares of the company's common stock to the company's new Chief Medical Officer, Essra Ridha, M.D., as an inducement award under the company's 2019 Inducement Plan. The grant was made in accordance with Nasdaq List

Business Wire
Neutral
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
2021-11-04 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended Sept. 30, 2021, and provided a business update. “We believe the data update provided at the 2021 European Society of Gene & Cell Therapy (ESGCT) Virtual Congress in October continues to strengthen the risk/benefit profile of our first-in-class lentiviral gene the

Business Wire
Neutral
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
2021-11-03 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-05, its lentiviral gene therapy for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter syndrome, a rare and seriously debilitating lysosomal disorder that primarily affects young boys.

Business Wire
Neutral
AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer
2021-10-26 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today announced the appointment of Essra Ridha, M.D., MRCP, FFPM, as chief medical officer. Dr. Ridha brings wide-ranging expertise in early- and late-stage clinical development of ex vivo lentiviral gene therapies. As vice president, clinical development at AVROBIO, she has guided the strategic and scientific development

Business Wire
Neutral
AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit
2021-10-20 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will present at the Jefferies Virtual Gene Therapy/Editing Summit at 10:30 a.m. ET on Thursday, Oct. 28, 2021. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors & Media section of the Company's website at www.

Business Wire
Neutral
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
2021-10-19 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported new safety data from the first lentiviral gene therapy clinical trials for Fabry disease and Gaucher disease, as well as new high-resolution cellular data providing insights into the mechanisms of action of its gene therapies. The data are being presented at the virtual 28th Annual Congress of the European

Business Wire
Neutral
AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
2021-10-06 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present new safety data from AVROBIO's clinical trials in Fabry disease and Gaucher disease type 1 at the virtual 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 19-22, 2021. Clinical and preclinical data from across the company's pipeline of lysosomal di

Business Wire
Neutral
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-10-05 07:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 201,750 shares of the company's common stock to eight new employees as inducement awards under the company's 2019 Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). The

Loading more news...